MerTK inhibitors represent a specialized category of chemical compounds designed to specifically target and impede the activity of the MerTK receptor tyrosine kinase. MerTK, an abbreviation for Mer Tyrosine Kinase, is a prominent member of the TAM (Tyro3, Axl, and Mer) family of receptor kinases, which exert pivotal control over numerous cellular processes. Predominantly expressed on the surfaces of phagocytic cells, such as macrophages and dendritic cells, MerTK activation plays a central role in recognizing and engulfing apoptotic cells and cellular debris, a fundamental aspect of the body's immune response and tissue equilibrium. However, when MerTK becomes dysregulated or experiences overexpression, it has been linked to various diseases, including cancer, autoimmune disorders, and chronic inflammation.
Consequently, MerTK inhibitors have been meticulously engineered to selectively disrupt MerTK's signaling pathways. These inhibitors primarily function by binding to the catalytic site of MerTK, effectively obstructing the receptor's ability to phosphorylate downstream signaling molecules. Consequently, they interrupt its cellular functions, exerting influence over vital processes such as phagocytosis, cytokine production, and interactions between immune cells. The ramifications of MerTK inhibition extend to diseases characterized by irregular cell clearance, immune evasion, or tissue remodeling. Researchers are continually refining MerTK inhibitors, exploring their capacity to address health challenges associated with MerTK-related cellular pathways.
Items 1 to 10 of 13 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | ¥282.00 ¥1320.00 ¥2358.00 | 27 | |
抑制酪氨酸激酶,尤其是 BCR-ABL 和 c-KIT,阻断癌细胞的细胞信号传导途径。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | ¥632.00 ¥2933.00 ¥4693.00 | 129 | |
靶向 RAF 激酶和血管内皮生长因子受体,阻碍癌症细胞增殖和血管生成。 | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | ¥699.00 ¥1264.00 ¥2414.00 ¥3858.00 | 74 | |
抑制表皮生长因子受体(EGFR),阻止肺癌细胞的生长和分裂。 | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | ¥2708.00 ¥11620.00 | 7 | |
阻断雄激素受体,阻碍其在前列腺癌细胞中的激活。 | ||||||
BMS 777607 | 1025720-94-8 | sc-364438 sc-364438A | 10 mg 50 mg | ¥4423.00 ¥14035.00 | 1 | |
BMS-777607是一种多靶点酪氨酸激酶抑制剂。其作用机理是结合MET、AXL、Ron和Tyro3激酶的ATP结合位点,从而抑制MerTK。其多靶点特性表明可以阻断更广泛的致癌途径。 | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | ¥1444.00 ¥7198.00 | 7 | |
抑制 mTOR,减少各种癌症的细胞生长和血管生成。 | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | ¥959.00 ¥1489.00 ¥3238.00 ¥5585.00 ¥42330.00 | 42 | |
靶向表皮生长因子受体,阻碍非小细胞肺癌的细胞生长。 | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | ¥2775.00 ¥5528.00 ¥6047.00 | 16 | |
抑制 JAK1 和 JAK2,调节骨髓增生性肿瘤中的细胞因子信号转导。 | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | ¥530.00 ¥1636.00 | 51 | |
阻断包括 BCR-ABL 在内的多种酪氨酸激酶,抑制慢性髓性白血病的生长。 | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | ¥4648.00 | 32 | |
同时以表皮生长因子受体和 HER2 为靶细胞,破坏乳腺癌细胞的信号通路。 |